Sildenafil for Period Pain: Four Research and Safety Checks

Before acting on a “Viagra for cramps” headline, check the preparation, the observation period and whether a newer study has reported results. Those details change what the evidence can support.

The published result came from 25 participants and four hours

The 2013 Croatian trial¹ randomized 25 women aged 18–35 with moderate-to-severe primary dysmenorrhea: 13 received a vaginal sildenafil preparation and 12 placebo. The abstract mentions 62 patients, but the methods identify 62 as the recruitment target; the results give 25 randomized and completed.¹

Total pain relief over four hours averaged 11.9 versus 6.4, favoring sildenafil. This was a weighted relief score, not a percentage pain reduction. Funding ended before recruitment reached its target. NIH supported the study; the authors declared no relevant conflicts.¹

No side effects were reported during that short observation. That cannot establish safety over repeated cycles. The trial also excluded suspected secondary causes of pain and did not compare sildenafil with an NSAID.¹

The current follow-up registration has no placebo arm

NCT07508358’s September 25, 2026 update describes an open-label, single-group mechanistic study with an estimated 10 participants. It lists not yet recruiting and no posted results when checked October 16. An earlier indexed description called it a randomized crossover trial; that is not the current design.²

The registered primary outcome is the change in uterine contractions measured during a ten-minute MRI recording. Secondary measures include pain, blood pressure and plasma sildenafil concentrations. These are planned measurements, not findings. The current study has no placebo group, so a future improvement from baseline alone would not establish a placebo-controlled treatment effect.²

An oral-tablet label does not validate vaginal use

US VIAGRA labeling covers oral treatment of erectile dysfunction, not menstrual pain. It contraindicates use with nitrates or riociguat because of blood-pressure effects. Alpha-blockers and blood-pressure medicines can also increase hypotension risk; other medicines can raise sildenafil exposure.³

The label advises prompt medical attention for sudden hearing loss and stopping use and seeking care for sudden vision loss. These oral-product warnings cannot supply the missing vaginal safety data. A prescriber would need to assess the proposed preparation, route, interactions and monitoring separately.³

Persistent cramps need an assessment and a usable treatment plan

The NHS⁴ lists anti-inflammatory medicines, hormonal contraception and TENS among options a clinician may suggest. It advises assessment when pain stops usual activities, periods become more painful or irregular, or pain occurs with sex, urination or bowel movements.⁴

For severe or worse-than-usual pain that painkillers have not helped, seek urgent advice. In England, the NHS⁴ directs people to an urgent GP appointment or NHS 111.⁴

Bring the response to previous treatment

In “The Pain Kit” in Period, Handled, the Period Scorecard records pain from zero to ten, what you tried and what the pain stopped you doing. Bring that account to the visit, including timing and adverse effects. Ask what needs investigating and which established option is suitable before pursuing an experimental preparation.

Our period-pain medicine guide covers the larger NSAID and combined-pill evidence base.